Research stack

SURMOUNT Dual-Incretin Weight Reduction (Tirzepatide)

Weight reduction using the GIP/GLP-1 co-agonist escalation characterized in the SURMOUNT trials.

Component peptides

Weight reduction via dual-incretin escalation.

Dual GIP and GLP-1 receptor agonism produces larger satiety and glycemic effects than GLP-1 alone.

Tirzepatide — 2.5 mg weekly sc for 4 weeks, then escalate by 2.5 mg every 4 weeks to target 10-15 mg weekly.

Last updated: 2026-09-15

Component peptides	Tirzepatide
Duration reported	72 weeks
Cycle pattern	Continuous escalation over 72 weeks per SURMOUNT-1
Difficulty	foundational
Regulatory status	Research use only. None of these compounds is FDA-approved for combined use described.

Peptide Codex Assistant

Research-literature companion

Hello. Ask me about a peptide, a stack, or a research protocol on Peptide Codex.

0 / 20 questions used todayResearch use only. Not medical advice.